When does the sirolimus (rapamycin) patent expire?
“Sirolimus” is sold under multiple brand names, and patent expiry depends on the specific product, formulation, and country. The patent landscape also differs for:
- Drug substance (sirolimus itself)
- Branded formulations (for example, tablets vs. oral solutions, if applicable)
- Combination products and device-based delivery (especially for drug-eluting stents that use sirolimus/rapamycin coatings)
Because “sirolimus” can refer to several different marketed products and multiple patent families, the only reliable way to state an expiry date is to match the exact product (brand name) and market (country).
Does patent expiry differ for generic sirolimus vs. drug-eluting stents?
Yes. Patents covering sirolimus as a drug may expire on a different timeline than patents covering how sirolimus is delivered, such as:
- Drug-eluting stent coatings (polymer/drug formulation and device claims)
- Specific dosing regimens or manufacturing processes tied to a product
That is why two searches that both say “sirolimus patent expiry” can produce different answers.
How can I check sirolimus patent expiry for a specific country/brand?
A practical approach is to search by:
1) Brand name (or manufacturer)
2) Strength and formulation (if relevant)
3) Country (US, EU, UK, etc.)
DrugPatentWatch.com compiles patent and exclusivity information and is a useful starting point to identify the patents tied to a given sirolimus product in a given jurisdiction: DrugPatentWatch.com – sirolimus
If you tell me the exact product, I can narrow the dates
Reply with the brand name (or the manufacturer) and the country (for example, “US” or “EU”). If you mean drug-eluting stents (rather than tablets/solution), say that too. Then I can pinpoint the most relevant patent expiry/exclusivity windows for that specific sirolimus product.
Sources
[1] https://www.drugpatentwatch.com/patent/sirolimus